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ABSTRACT
Objectives: To investigate the expression of microsomal
prostaglandin E (PGE) synthase 1 (mPGES-1) and
cyclooxygenase (COX) in muscle biopsies from patients
with polymyositis or dermatomyositis before and after
conventional immunosuppressive treatment.
Methods: mPGES-1 and COX expression was evaluated
by immunohistochemistry in muscle tissue from healthy
individuals and from patients with polymyositis or
dermatomyositis before and after conventional immuno-
suppressive treatment. The number of inflammatory cell
infiltrates, T lymphocytes and macrophages was esti-
mated before and after treatment. To localise the mPGES-
1 expression double immunofluorescence was performed
with antibodies against mPGES-1, CD3, CD68, CD163 and
a fibroblast marker. A functional index was used to assess
muscle function.
Results: In patients with myositis, mPGES-1, COX-2 and
COX-1 expression was significantly higher compared to
healthy individuals and associated with inflammatory
cells. Double immunofluorescence demonstrated a pre-
dominant expression of mPGES-1 in macrophages.
Conventional immunosuppressive treatment resulted in
improved but still lower muscle function than normal. A
decreased number of CD68-positive macrophages and
reduced COX-2 expression in muscle tissue was also
seen. By contrast, following the same treatment no
significant changes were observed in muscle tissue
regarding number of infiltrates, T lymphocytes, CD163-
positive macrophages or mPGES-1 protein levels.
Conclusions: Increased expression of mPGES-1, COX-1
and COX-2 at protein level was observed in muscle tissue
from patients with myositis compared to healthy
individuals. Conventional immunosuppressive treatment
led to a significant downregulation of COX-2 in myositis
muscle tissue. However, the expression of mPGES-1 and
COX-1 remained unchanged indicating a role of these
enzymes in the chronicity of these diseases.
Polymyositis and dermatomyositis are chronic
muscle disorders characterised by muscle weakness
and fatigue and by skin involvement in the case of
dermatomyositis.
1 These diseases are also charac-
terised by infiltration of inflammatory cells in
skeletal muscle tissue, muscle fibre degeneration
and regeneration. The pathogenesis of myositis has
not been well characterised yet, but pro-inflam-
matory cytokines have been consistently found in
the inflamed muscle and are implicated in the
pathogenesis.
2–4
Arachidonic acid metabolites such as prostaglan-
dins (PG) might also contribute to the pathogen-
esis of inflammatory myositis. Human skeletal
muscles have a considerable capacity to produce
PGE2, PGD2, PGF2a and PGI2.
5 PGE2 appears to be
involved in a number of biological processes,
including protein turnover and myogenesis, and is
a potent mediator of muscular pain and inflamma-
tion.
6–10 Interleukin (IL)1b and tumour necrosis
factor (TNF), which are markedly expressed in
myositis muscle tissue, stimulate PGE2 production
in skeletal muscles.
2 3 11 12 In the PGE2 biosynthetic
pathway, cyclooxygenase (COX)-1 and COX-2
catalyse the conversion of arachidonic acid into
PGH2 (fig 1). Recently, enhanced expression of
COX-1 and COX-2 mRNA was demonstrated in
inflamed muscle tissue from patients with myosi-
tis, suggesting a role for them in this disease.
13
Three terminal PGE synthases (PGES) catalyse the
formation of PGE2 from PGH2 Microsomal PGE
synthase 1 (mPGES-1) is strongly induced by
proinflammatory stimuli in various cells and
preferentially couples with COX-2 contributing
to significant PGE2 release.
14–16 Cytosolic PGES
(cPGES) and mPGES-2 are constitutively expressed
and likely to function in the basal production of
PGE2
17 18 Studies of mPGES-1 –/– knock-out mice
have demonstrated a critical role for mPGES-1 in
the development of pain, fever and inflamma-
tion.
19 20 mPGES-1 is upregulated in a range of
inflammatory diseases and considered a new target
for therapeutic strategies to control induced PGE2
synthesis.
21–23 However, the expression of mPGES-1
in muscle tissue from patients with myositis has
not been studied.
Despite clinical improvement with conventional
immunosuppressive treatment including high
doses of glucocorticoids (GC), many patients with
myositis experience persistent muscle weakness.
There are also reports of persisting inflammatory
cells and increased expression of IL1 in muscle
tissue despite long-time treatment with high doses
of GC.
32 4 Intra-articular treatment with GC
significantly reduces mPGES-1, COX-1 and
COX-2 expression in the synovial tissue from
patients with rheumatoid arthritis and is asso-
ciated with clinical improvement.
25 Whether
mPGES-1 and COX expression in skeletal muscle
from patients with myositis is affected by immu-
nosuppressive treatment has not been investigated
to date.
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localisation of mPGES-1 and COX in skeletal muscle tissue
from patients with polymyositis or dermatomyositis and from
healthy subjects. In addition we studied the effects of
immunosuppressive treatment on mPGES-1 and COX expres-
sion in skeletal muscle tissue from patients with myositis in
relation to the effects on clinical function.
PATIENTS AND METHODS
Patients and muscle biopsies
In the first cohort, nine patients with recently diagnosed
polymyositis or dermatomyositis and three with treatment-
resistant myositis (disease duration 3–6 years) meeting the
Bohan and Peter criteria were included (median age 54 years,
range 44–76 years).
26 27 Clinical data of the patients are
presented in tables 1 and 2. Detailed clinical data for these
patients have been reported previously.
28
To investigate the effects of immunosuppressive treatment a
second cohort of 10 patients with recently diagnosed poly-
myositis or dermatomyositis with available follow-up biopsies
was included (median age 56.5 years, range 23–88 years). The
patients were initially treated with oral prednisolone (40–
60 mg/day) with slowly tapering doses and all patients (except
two) received an additional immunosuppressive agent (tables 1
and 2). Two patients were treated with non-steroidal anti-
inflammatory drugs (NSAIDs) at the time of the first biopsy.
Muscle tissue biopsies were taken from m. vastus lateralis
before and after a median of 8.5 months (range 4–11 months)
with immunosuppressive treatment. Muscle tissue biopsies
were obtained under local anaesthesia using the semi-open
biopsy technique.
28 29
Muscle biopsies from seven healthy individuals (four women
and three men, median age 46 years, range 38–50 years) without
clinical or histopathological signs of muscle disease were
included as controls. Muscle biopsies were obtained from
musculus vastus lateralis in six individuals and from musculus
tibialis anterior in one individual.
The approval was granted by the Ethics Committee at the
Karolinska University Hospital, Stockholm and all patients and
controls gave their informed consent to participate in the study.
Clinical assessment of patients
Muscle performance (functional index (FI) of myositis) was
assessed by the number of repetitions performed in defined
muscle groups before treatment and at the time of the second
biopsy.
30 The individual total score is presented as percentage of
the maximal score 64 (mean values of left and right side). The
responder criterion was set to 20% improvement.
Immunohistochemical analysis
Staining of serial cryostat sections with mouse monoclonal anti-
CD3 (BD Biosciences, San Jose ´, California, USA), anti-CD68
(marker of monocyte/macrophage lineage, KP-1 clone, Dako
Cytomation, Glostrup, Denmark) and anti-CD163 (resident
tissue macrophage marker, BerMac3 clone, Dako Cytomation)
antibodies was performed using a standard protocol.
31 Staining
with rabbit polyclonal anti-human mPGES-1 antiserum,
22
polyclonal anti-cPGES, anti-COX-2 and anti-COX-1 (Cayman
Chemicals, Ann Arbor, Michigan, USA) and mouse monoclonal
anti-COX-1 antibodies (Wako Chemicals, Neuss, Germany) was
performed as previously described.
32 Staining in skeletal muscle
tissue was halted by preincubation of anti-mPGES-1 serum with
mPGES-1 protein and by preincubation of commercial anti-
bodies with respective blocking peptides (Cayman Chemical).
Isotype-matched irrelevant antibodies were used as negative
controls. The first and the last sections from each series of
consecutive sections were stained with haematoxylin and eosin
to evaluate the number of inflammatory infiltrates.
Stained tissue sections were examined using a Polyvar II
microscope (Reichert-Jung, Vienna, Austria) and photographed
with a digital Leica camera 300F (Leica, Cambridge, UK). The
number of PGES and COX positive cells was assessed by
conventional microscopy measurements of the entire tissue
section (2–9 mm
2) using semi-quantitative scale: 0, no staining;
1, a few stained scattered cells; 2, many stained scattered cells;
3, many stained scattered cells and cells in one infiltrate; 4,
strong staining in many scattered cells and several infiltrates.
Evaluation of coded sections was performed by two indepen-
dent observers. The mean scores from the two assessments were
used for statistical analysis.
Expression of CD3, CD68 and CD163 was assessed quantita-
tively using computer-assisted image analysis. The images were
analysed with a Quantimet 600 image analyser (Leica) and
positive staining was expressed as percentage of total counter-
stained tissue area.
Double immunofluorescence was performed using anti-
human mPGES-1 antiserum and mouse monoclonal anti-CD3,
anti-CD68, anti-CD163 and anti-prolyl-4-hydroxylase (fibro-
blast marker, 5B5 clone, Dako Cytomation) antibodies as
published previously.
22
Statistical analysis
Data were analysed using the Mann–Whitney U test and
Wilcoxon signed rank test and Bonferroni corrections for
Figure 1 A schematic overview of the prostaglandin (PG) biosynthesis
cascade.
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tically significant. Correlation between muscle FI and enzyme
expression in muscle tissue was analysed using Spearman rank
correlation test.
RESULTS
Expression of PGES and COX
A marked mPGES-1 staining localised in many scattered
mononuclear cells and in mononuclear cells in infiltrates was
observed in all patients with some interindividual variations
(fig 2A). For 6 patients mPGES-1 staining was additionally
localised to smooth muscle cells in large vessels, and for 10
patients to capillaries as well. In muscle tissue from healthy
individuals, weak mPGES-1 staining was detected in a few
scattered mononuclear cells and capillaries (fig 2B), as well as in
smooth muscle cells in large vessels in two individuals. Using
conventional microscopic assessment, we found that mPGES-1
expression in muscle tissue from patients with myositis (n=12)
was significantly higher (p,0.01) when compared to healthy
individual tissue (n=7) (fig 3).
Staining of cPGES was observed in scattered mononuclear
cells, cells surrounding large vessels and muscle fibres in
myositis and healthy muscle tissues with a similar distribution
pattern (data not shown). In two patient biopsies, cPGES
positive cells were detected in inflammatory cells in infiltrates.
The staining for cPGES in the myositis muscle was not
significantly different when compared to healthy controls
(fig 3).
COX-1 expression was detected in muscle fibres, blood vessels
and scattered mononuclear cells in patients and healthy
subjects. In patients a strong COX-1 staining was additionally
observed in mononuclear cells within the inflammatory
infiltrates (fig 2C, D). COX-2 was expressed in macrophage-
like cells within inflammatory infiltrates, in scattered mono-
nuclear cells and in some large vessels in myositis muscle tissue.
By contrast, in healthy muscle tissue COX-2 staining was only
detected in few scattered mononuclear cells and in some vessels
(fig 2E, F). COX-1 and COX-2 expression were significantly
enhanced (p,0.01) in myositis muscle tissue when compared to
healthy control (fig 3).
Double immunofluorescence revealed the expression of
mPGES-1 in CD163-positive (fig 4A–C) and of CD68-positive
macrophages (data not shown). However, we could not detect
any mPGES-1 staining in T lymphocytes or fibroblasts (data not
shown).
Effects of immunosuppressive treatment on PGES and COX
expression
The expression of mPGES-1 in myositis muscle tissue was not
altered by the treatment (n=10) (fig 5A). In patients without
infiltrates after treatment (4 out of 10), mPGES-1 staining was
still apparent in scattered mononuclear cells. Likewise, the
distribution pattern or score for cPGES and COX-1 positive cells
remained unchanged (fig 5A). By contrast, the score for COX-2
positive cells in muscle tissue was significantly reduced
(p,0.01) after treatment (fig 5A, B). There was no significant
difference between polymyositis and dermatomyositis regarding
the expression pattern of these enzymes before or after
treatment.
Effects of immunosuppressive treatment on muscle
histopathology
Before treatment, 8 out of 10 patients presented infiltrates of
mononuclear cells. After 4–11 months of immunosuppressive
treatment the number of inflammatory infiltrates tended to be
lower (median 0.52, range 0–2.6 infiltrates/mm
2 vs median 0.22,
range 0–2.4 infiltrates/mm
2 before and after treatment, respec-
tively), but this difference did not reach statistical significance.
Table 1 Clinical data on the patients at the time of biopsies, cohort 1: patients with recently diagnosed and
with treatment-resistant myositis (marked with *)
Patient Age Sex Bohan and Peter diagnostic criteria Biopsy site
Treatment at time of biopsy,
mg/day
1 53 F Probable polymyositis Mus vastus lat None
2 59 F Probable polymyositis Mus deltoideus Pred 5, NSAID
3 76 F Definite polymyositis Mus vastus lat None
4 44 F Definite polymyositis Mus vastus lat None
5 65 F Definite dermatomyositis Mus vastus lat Pred 15
6 72 F Definite polymyositis Mus vastus lat Pred 15–40, AZA
7 60 M Probable polymyositis Mus vastus lat NSAID
8 56 M Definite polymyositis Mus vastus lat NSAID
9 55 M Probable dermatomyositis Mus vastus lat None
10* 67 M Definite dermatomyositis Mus vastus lat AZA, MTX, Cs
11* 54 F Probable polymyositis Mus tib ant AZA, MTX, Cs
12* 61 F Definite polymyositis Mus vastus lat AZA, MTX, Cs
Ant, anterior; AZA, azathioprine; Cs, ciclosporine; F, female; lat, lateralis; M, male; Mus, musculus; MTX, methotrexate; NSAID,
non-steroidal anti-inflammatory drugs; tib, tibialis; Pred, prednisolone.
Table 2 Clinical data on the patients at the time of biopsies, cohort 2:
myositis patients before and after conventional immunosuppressive
treatment
Patient Age Sex
Bohan and Peter
diagnostic criteria
Treatment at
time of biopsy 1,
mg/day
Treatment at
time of biopsy 2,
mg/day
1 60 F Definite polymyositis None Pred 12.5, MTX
2 23 F Probable dermatomyositis None Pred 5, AZA
3 49 F Definite dermatomyositis NSAID Pred 15, NSAID
4 53 F Definite polymyositis None Pred 20, AZA
5 41 F Probable dermatomyositis None Pred 30
6 44 F Probable dermatomyositis None Pred 7.5
7 67 M Probable polymyositis None Pred 10
8 88 F Definite dermatomyositis None Pred 7.5
9 60 M Probable polymyositis NSAID Pred 30
10 62 M Definite dermatomyositis None Pred 10, AZA
AZA, azathioprine; F, female; M, male; MTX, methotrexate; NSAID, non-steroidal anti-
inflammatory drugs; Pred, prednisolone.
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detected in infiltrates, in scattered cells and in cells surrounding
large vessels. The total number of monocytes/macrophages
(CD68 positive cells) was significantly reduced after the
treatment (p,0.01), while the positively stained area was not
altered for T lymphocytes or CD163-positive resident macro-
phages (fig 5C).
Effects of immunosuppressive treatment on muscle function
Before treatment, muscle weakness in patients was confirmed
by a reduced FI (median 38.4%, range 22–65%), performed in all
but one patient (n=9). After 4–11 months of immunosuppres-
sive treatment, a significantly increased FI was recorded
(median 86.3%, range 37.5–100%, p,0.05), reflecting improved
muscle function (fig 5D). On an individual basis, 8 out of 10
patients had improved by more than 20% in FI score. For one
patient a decreased FI score was noted and for another the
results of the first FI was not available. Despite the marked
improvement in muscle function during the treatment period, a
majority of the patients still had FI scores below the maximal
value. Only one patient improved up to maximal score (100%).
There was no correlation between enzyme expression in
muscle tissue and FI before or after treatment and the changes
in enzyme expression did not correlate with changes in FI after
treatment. In the patient who deteriorated clinically, the score
for COX-2 expression was decreased after the treatment (from
2.5 to 1.5), in similar fashion to other patients who clinically
improved.
DISCUSSION
The present study demonstrates significantly increased expres-
sion of mPGES-1, COX-2 and COX-1 in skeletal muscle tissue
from patients with polymyositis or dermatomyositis compared
to that from healthy individuals. In healthy muscle tissue COX-
1 and cPGES proteins were detected in scattered mononuclear
cells, in vessels and in muscle fibres, suggesting that these
enzymes account for the basal production of PGE2. In healthy
muscle tissue we also observed mPGES-1 and COX-2 staining in
few scattered mononuclear cells and blood vessels, indicating
constitutive expression of these enzymes in muscle tissue.
Constitutive expression of mPGES-1 and COX-2 has been
reported in other tissues, eg, kidney, suggesting their possible
role for basal PGE2 production under non-pathological condi-
tions.
33 34 Moreover, increased expression of COX-2 and mPGES-
1 has been demonstrated in response to non-inflammatory
stimuli, such as mechanical stretch and mechanical stress in
certain cells.
83 53 6
Figure 2 Immunohistochemical staining (brown) for (A, B) microsomal prostaglandin E synthase (mPGES)-1, (C, D) cyclooxygenase (COX)-1 and (E,
F) COX-2 in representative muscle tissue sections counterstained with haematoxylin (A, C, E) from patients with polymyositis and (B, D, F) from healthy
individuals (original magnification 6500).
Figure 3 Expression of microsomal prostaglandin E synthase (mPGES)-
1, cytosolic PGES (cPGES), cyclooxygenase (COX)-1 and COX-2 in
muscle tissue from patients with polymyositis or dermatomyositis and
from healthy individuals. Results are expressed as positive cell score
mean (standard error of mean (SEM)). *p,0.05, patients vs healthy
individuals.
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muscle tissue from patients with myositis is in accordance with
previously published data demonstrating increased levels of
COX-1 and COX-2 mRNA in inflammatory cells and vessels in
muscle tissue from patients with myositis.
13 Notably there have
been no clinical trials addressing specifically the impact of
selective or non-selective NSAIDs in patients with myositis. In
addition, mPGES-1 expression was enhanced in myositis muscle
tissue, as an increased number of positively stained scattered
mononuclear cells and as positively stained cells within
inflammatory infiltrates compared to low constitutive expres-
sion in healthy muscle tissue. Using double staining, we
identified CD68 and CD163-positive macrophages as the major
cell types expressing mPGES-1. IL1b and TNF are strongly
expressed in myositis skeletal muscle tissue
23and known to
maintain mPGES-1 expression in macrophages, consequently
contributing to the enhanced release of PGE2 and inflammation
in the muscle tissue.
We also examined the effects of conventional immunosup-
pressive treatment on muscle functional activity, muscle
histopathology and expression of mPGES-1/COX in muscle
tissues. Treatment resulted in significant improved muscle
function in the majority of the patients. However, most
patients still had impaired muscle function at the time of the
second biopsy. Significant reduction in the total number of
macrophages (CD68 positive cells) confirmed anti-inflamma-
tory effects of the treatment. After treatment the COX-2
positive cells in muscle tissue were significantly decreased, while
the expression of mPGES-1, cPGES or COX-1 was not
suppressed. Downregulation of COX-2 expression is one of
the expected anti-inflammatory effects of GC and is associated
with suppression of PGE2 biosynthesis.
However, there was no correlation between COX-2 expres-
sion in muscle tissue and FI before or after treatment, probably
due to the small number of observations.
The reduced number of COX-2 positive cells could be
explained by GC dependent downregulation of COX-2 expres-
sion and/or a significant reduction in total number of
macrophages (CD68 positive cells). By contrast, resident
tissue macrophages (CD163-positive cells) did not decrease
Figure 4 Double fluorescence staining demonstrating cellular localisation of microsomal prostaglandin E synthase (mPGES)-1: (A) mPGES-1 positive
(green) cells, (B) CD163 positive (red) cells and (C) double stained (yellow) cells in representative muscle tissue section from the patient with
polymyositis (original magnification 6250).
Figure 5 A. Expression of microsomal
prostaglandin E synthase (mPGES)-1 and
related enzymes in muscle tissues of
patients with polymyositis or
dermatomyositis before and after
conventional treatment. Results are
expressed as positive cell score mean
(standard error of mean (SEM)). B.
Expression of cyclooxygenase (COX)-2 in
muscle tissues of patients with
polymyositis or dermatomyositis before
and after conventional treatment. Results
are expressed as positive cell score. C.
Number of inflammatory cells in muscle
tissue from patients with polymyositis
and dermatomyositis before and after
conventional treatment. Results are
expressed as percentage of the total area
of counterstained tissue. D. Effects of
conventional treatment on muscle
function in patients with polymyositis or
dermatomyositis. Results are expressed
as percentage of functional index (FI) for
each patient. *p,0.05, before vs after
treatment.
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population of CD68 cells that decreased as a result of the
treatment constitutes cells that did not express CD163 or
mPGES-1, as these molecules were not changed after treatment.
A similar relative persistence of synovial CD163-positive
resident tissue macrophages compared to infiltrating macro-
phages during anti-TNF treatment has been demonstrated in
chronic autoimmune arthritis.
37 In addition, immunosuppres-
sive treatment did not affect the number of T lymphocytes in
myositis muscle providing a basis for persisting immune
reaction that targets muscle fibres.
Interestingly, in some conditions mPGES-1 functionally
utilises PGH2 generated by COX-1.
34 38 39 The persisting expres-
sion of mPGES-1 and COX-1 in inflamed muscle tissue despite
treatment might preserve PGE2 production and contribute to
chronic muscle inflammation. However, the role of the mPGES-
1/COX-1 pathway in overall PGE2 production in muscle tissue
remains to be elucidated.
Recent data suggest that COX-2–dependent PG synthesis is
important for skeletal muscle regeneration.
40–42 While COX-2
inhibition reduces inflammation to a large extent due to the
suppression of PGE2 formation, it might impede the functional
recovery of muscles via the suppression of other PGs. In this
context mPGES-1 may constitute a more selective and safe
therapeutic target than COX-2. Selective inhibition of mPGES-1
will allow for intact baseline PGE2 production as well as intact
production of other PG important for muscle regeneration and,
ultimately, constitute a more preferable anti-inflammatory
treatment than the currently used systemic GCs.
In conclusion, we have demonstrated a significantly enhanced
expression of mPGES-1, COX-2 and COX-1 in patients with
polymyositis or dermatomyositis compared to healthy controls,
suggesting its role in the pathogenesis of these diseases.
Moreover, we have shown for the first time that conventional
immunosuppressive treatment led to a significant downregula-
tion of COX-2 in myositis muscle tissue, while the expression of
mPGES-1 and COX-1 remained unchanged. This persisting
expression of mPGES-1 and COX-1 may have a role in the
chronicity of myositis.
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